ContextPrescription drugs are instrumental to managing and preventing chronic disease.
Recent changes in US prescription drug cost sharing could affect access to them …

This paper describes three prototypical systems of therapeutic reference pricing (RP) for
pharmaceuticals Germany, the Netherlands, and New Zealand and examines their effects …

This new edition examines the economics of health care systems in a non-technical manner.
It is written in a highly accessible manner for economists and non-economists alike. It is very …

Policy Points: Our study indicates that there are opportunities for cost savings in generic
drug markets in Europe and the United States. Regulators should make it easier for generic …

Background Increasing patient cost sharing is a commonly employed mechanism to contain
health care expenditures. Objective To explore whether the impact of increases in …

Background Pharmaceuticals are important interventions that could improve people's health.
Pharmaceutical pricing and purchasing policies are used as cost‐containment measures to …

Prescription medications enhance the well-being of most chronically ill patients. Many
individuals, however, struggle with how to pay for their treatments and as a result experience …

This article provides a review of research that has addressed the impact of patient
costsharing on the use of services and resulting health status impacts, among the population …

States are reacting to increased Medicaid drug costs by implementing cost-control policies,
such as preferred drug lists (PDLs) and prior authorization. PDLs have risks as well as …

This work aims to provide a systematic and updated survey of original scientific studies on
the effect of the introduction of reference pricing (RP) policies in Organisation for Economic …